Susceptibility pattern of methicillin resistance Staphylococcus aureus (MRSA) by flow cytometry analysis and characterization of novel lead drug molecule from Streptomyces species.

BACKGROUND: Actinomycetes particularly, Streptomyces species are producing wide variety of natural products with potential bioactivities. The microbial-derived metabolites hold a strong position to combat emerging and re-emerging antimicrobial drug-resistant pathogens. OBJECTIVES: A diverse group of actinomycetes strains were isolated from unexplored regions of mangrove sediment. Further, a polyphasic approach based on 16S rRNA gene sequence analysis and to evaluate their antibacterial potential against a panel of bacterial pathogens and methicillin resistance Staphylococcus aureus (MRSA). METHODS: The mangrove sediment samples were serially diluted with sterile water and plated on inorganic starch agar medium. A total of 20 isolates were pure cultured and 16S rRNA gene sequences were deposited in the public nucleotide databases (GenBank, NCBI). All the isolates were screened for the antibacterial activity by agar overlay method. Further, the susceptibility pattern of MRSA by flow cytometry and fluorescence microscopy was analysed. RESULTS: These twenty different isolates were grouped under nine major clad and they shared 95-99% sequence identity to the 16S rRNA gene sequences of the genus Streptomyces in the public nucleotide databases. Among these strains, the isolates namely JRG-02, JRG-03, JRG-04, JRG-10 and JRG-12 exhibited a broad-spectrum antibacterial activity against Methicillin-resistant Staphylococcus aureus(MRSA) and Gram negative bacteria Klebsiella pneumoniae MTCC109. Furthermore, we have characterized the antibacterial compound production and its properties from the isolate JRG-02, a potential drug candidate. The culture conditions and various nutrient components of strain Streptomyces sp. JRG-02 were optimized for enhanced antibiotics production of the isolate. The FT-IR and LCMS spectrum analysis envisaged the chemical nature of the substance. The effect of antibacterial compound on the viability of MRSA was alone examined by flow cytometry (FACS) and fluorescence microscopy analysis. CONCLUSIONS: The present study clearly shows that the survival of diverse inhabitants of Streptomyces in the mangrove sediments. Hence, the mangrove sediment inhabiting strain Streptomyces sp. JRG-02 has potential pharmaceutical activity and genetic diversity.

In-vitro assessment of antimicrobial properties and lymphocytotoxicity assay of benzoisochromanequinones polyketide from Streptomyces sp JRG-04.

The chromanequinone (BIQ) compound produced by the mangrove estuary derived strain, Streptomyces sp. JRG-04 was effective even at low MIC level concentration against Methicillin resistant S. aureus and other clinical pathogens. In this study, we have investigated the antimicrobial potential of chromanequinone compound by using various microscopy and imaging techniques. The flow cytometry (FACS) analysis suggested the BIQ aromatic polyketide compound produced by the Streptomyces sp. JRG-04 has toxic effect on MRSA cell membrane by increased up take of propidium iodide dye. The bacterial imaging analysis by high content screening experiment (HCS) revealed the increased number of dead MRSA cells than the live MRSA populations with chromanequinone treatment. Furthermore, atomic force microscopic study proved the MRSA cell surface ultra-structure changes when the cells exposed to chromanequinone compound at 3 h and 6 h. Further, in-vitro lymphocytotoxicity effect of chromanequinone compound at different concentrations with the combination of complement was performed on human lymphocytes by cell lysis assay. Interestingly, we have found that the higher concentration of BIQ chromanequinone (10 mg/mL) compound without complement induced apoptosis of human lymphocytes. The present investigation reveals that the toxic potential of chromanequinone on human lymphocytes might be associated with the complement dependent. This study strongly suggests that the chromanequinone compound produced by the Streptomyces strain with bioactive property can be developed as a therapeutic leads for various pharmaceutical applications.

Antimicrobial potential of phylogenetically unique actinomycete, Streptomyces sp. JRG-04 from marine origin.

Due to the emergence of severe infectious diseases and thriving antibiotic resistance, there is a need to explore microbial-derived bioactive secondary metabolites from unexplored regions. Present study deals with a mangrove estuary derived strain of Streptomyces sp. with potent antimicrobial activity against various pathogens, including methicillin resistant Staphylococcus aureus. Bioactive compound was effective even at low MIC level, damages the membrane of methicillin resistant S. aureus and causes cell death, however it has no cytotoxic effect on H9C2 cells. 16S rRNA shared 99.5% sequence similarity to Streptomyces longispororuber. Optimum biomass and antimicrobial compound production were observed in production medium supplemented with 1.0% maltose and 0.5% yeast extract. The active compound purified from the chloroform extract of the cell-free supernatant was studied by FT-IR, 1H NMR, 13C NMR and LC ESI-MS and identified as aromatic polyketide. ß-ketosynthase (KS) domain of the Streptomyces strain revealed 93.2% sequence similarity to the benzoisochromanequinone, an actinorhodin biosynthetic gene cluster of Streptomyces coelicolor A3(2). However, the region synthesizing the secondary metabolite produced by the S. longispororuber was not related to the KS domain of the strain, due to the phenomenon of horizontal gene transfer over the period of evolutionary process, thus generating metabolic compound diversity.